CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 4,887 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $24.33, for a total transaction of $118,900.71. Following the transaction, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at $4,941,860.94. This represents a 2.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Raymond Woo also recently made the following trade(s):

• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $47,535.58.

CeriBell Stock Performance

CeriBell stock opened at $23.43 on Friday. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock has a fifty day moving average price of $21.03 and a two-hundred day moving average price of $19.61. The firm has a market capitalization of $899.24 million, a P/E ratio of -13.31 and a beta of 0.95.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group raised their target price on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average price target of $24.40.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in shares of CeriBell by 41.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares during the period. Sei Investments Co. grew its position in shares of CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after purchasing an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after buying an additional 1,393 shares during the period. Finally, Strs Ohio acquired a new position in shares of CeriBell during the first quarter worth about $27,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.